- $41.45m
- $29.09m
- $1.12m
Brief: RenovoRx Appoints Angela Gill Nelms As Chief Operating Officer
Brief: RenovoRx reports Q2 results
Brief: RenovoRx Appoints James Ahlers As CFO
Brief: RenovoRx to Present Preclinical Data For Its Platform's Potential Utility for Bile Duct Cancer Treatment
Brief: RenovoRx Reports Q1 2022 Financial Results
Brief: RenovoRx Reports Full Year 2021 Financial Results
Brief: Renovorx Enrolls First Patient In Ongoing Tiger-Pac Phase 3 Clinical Trial
Brief: RenovoRx Says As Of Sept 30, Co Had Cash, Cash Equivalents Of $17.7 Mln And No Outstanding Debt Obligations
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:01 PM
U.S. STOCKS ON THE MOVE-PubMatic, Unity Biotech, Seres Therapeutics
U.S. STOCKS ON THE MOVE-RingCentral, Open Lending, Wendy's
RenovoRx surges on social media chatter, pancreatic cancer presentation
U.S. STOCKS ON THE MOVE-Boeing, BioMarin, Shutterstock
RenovoRx surges on FDA approval for cancer treatment device
Brief: Renovorx Receives New 510(K) Clearance For Its Renovocath Delivery System Designed For Targeted Treatment Of Solid Tumors
U.S. STOCKS ON THE MOVE-Globalstar, AC Immune, Spok
NASDAQ RESUMED AT 03:44 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:39 PM
NASDAQ RESUMED AT 10:22 AM